Janus Henderson Group PLC Grows Stock Position in Disc Medicine, Inc. (NASDAQ:IRON)

Janus Henderson Group PLC increased its position in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 62.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,217,815 shares of the company’s stock after buying an additional 467,988 shares during the quarter. Janus Henderson Group PLC owned about 4.09% of Disc Medicine worth $77,170,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in IRON. Barclays PLC raised its position in shares of Disc Medicine by 123.7% during the 3rd quarter. Barclays PLC now owns 40,145 shares of the company’s stock valued at $1,972,000 after buying an additional 22,202 shares during the period. JPMorgan Chase & Co. raised its position in shares of Disc Medicine by 16.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after buying an additional 2,257 shares during the period. SG Americas Securities LLC raised its position in shares of Disc Medicine by 66.0% during the 4th quarter. SG Americas Securities LLC now owns 8,076 shares of the company’s stock valued at $512,000 after buying an additional 3,212 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after buying an additional 593 shares during the period. Finally, Bleakley Financial Group LLC purchased a new stake in Disc Medicine in the fourth quarter valued at approximately $486,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Up 5.4%

Shares of IRON opened at $46.61 on Tuesday. The firm’s 50-day moving average is $46.72 and its two-hundred day moving average is $54.99. Disc Medicine, Inc. has a twelve month low of $30.65 and a twelve month high of $68.73. The firm has a market capitalization of $1.61 billion, a P/E ratio of -11.71 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on IRON shares. Cantor Fitzgerald boosted their target price on Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. BMO Capital Markets boosted their target price on Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday. Stifel Nicolaus boosted their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Wedbush reissued an “outperform” rating and issued a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $98.80.

Insider Activity

In other Disc Medicine news, insider Pamela Stephenson sold 3,137 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,217.46. Following the transaction, the insider now owns 69,529 shares of the company’s stock, valued at $3,794,892.82. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $50.17, for a total transaction of $105,357.00. Following the transaction, the insider now directly owns 66,398 shares in the company, valued at approximately $3,331,187.66. This represents a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 356,290 shares of company stock worth $19,336,901 over the last ninety days. 4.24% of the stock is currently owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.